Loading…

The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage

Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical immunology 1997-03, Vol.17 (2), p.140-153
Main Authors: JIN, Y, FULLER, L, CARRENO, M, ZUCKER, K, ROTH, D, ESQUENAZI, V, KARATZAS, T, SWANSON, S. J, TZAKIS, A. G, MILLER, J
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c431t-b569cf8d1683aaf355b2aeffbc7643b77fc615e19df91172de7d6d40547891933
cites
container_end_page 153
container_issue 2
container_start_page 140
container_title Journal of clinical immunology
container_volume 17
creator JIN, Y
FULLER, L
CARRENO, M
ZUCKER, K
ROTH, D
ESQUENAZI, V
KARATZAS, T
SWANSON, S. J
TZAKIS, A. G
MILLER, J
description Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC anti-CD3 monoclonal antibodies (mAb). One was a bright fluorescence intensity population (as in PBL), and the other dim. We calculated the number of FITC-anti-CD3 mAbs bound per lymphocyte on PBL and LIL and found 80,040 +/- 4628 and 39,615 +/- 3932, respectively. Therefore, HCV+ and HCV- patient PBL contained approximately twice the number of CD3 molecules per cell than patient CD3+ LIL. LIL also contained approximately a threefold higher concentration of TCR alpha beta +, CD4-CD8-, and CD56,16 (NK) cells than the patient PBL. Thus, a major subset of LIL is phenotypically similar to mouse NK1.1+ "intermediate" T cells. LIL freshly isolated from HCV+ livers exhibited weak CTL activity against EBV- or Con A-transformed lymphoblast targets infected with vaccinia-HCV recombinant virus (rHCV) or primary hepatocyte cultured cells. However, after in vitro coculture of LIL with rHCV, these cells developed a strong cytotoxicity for the above targets. In contrast, LIL from HCV- livers were not cytotoxic against the same targets. Histochemical studies (in situ) demonstrated that these hepatocytes express CD95, and stains demonstrated apoptosis. The HCV+ hepatocytes also express class I MHC molecules and ICAM-1. The addition of mAb specific for these adhesion molecules inhibited CML activity. Short-term cultured hepatocytes (targets) from HCV+ and HCV- patients produced low levels of cytokines IL-1 beta, IL-2, IL-6, TNF alpha, and IFN-gamma but a high level of IL-8. It is speculated that LIL expressing reduced numbers of CD3 molecules may even function as immune regulators as proposed for intermediate T cells in mice.
doi_str_mv 10.1023/a:1027326415164
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78890579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2695191195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-b569cf8d1683aaf355b2aeffbc7643b77fc615e19df91172de7d6d40547891933</originalsourceid><addsrcrecordid>eNp1kM9rFTEUhYMo7bN13VUhqLgbmx-TZOJOHmqFgpvqdriT3PSlZGZek5nC---N-uii4Oosvo_DuZeQC84-cibkFXyqYaTQLVdcty_IhisjG6GseEk2FfHG8lacktel3DPGpBbqhJxY1snOsg2B2x3SOI7rhDQjuCU-xuVA85yQzoFeb381cfKrQ09TfMRM4xRiWjIscbqj6TDud7M7LFgqoDvcwzI7TGlNkKmHEe7wnLwKkAq-OeYZ-fn1y-32urn58e379vNN41rJl2ZQ2rrQea47CRCkUoMADGFwRrdyMCY4zRVy64Pl3AiPxmvfMtWaznIr5Rn58K93n-eHFcvSj7H82QITzmvpTVcPVsZW8d0z8X5e81S39UJbxWu9VdV6-1-rbrRS_626PErrMKLv9zmOkA_98b2Vvz9yKA5SyDC5WJ40oZntOiF_A0Z-iIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216893679</pqid></control><display><type>article</type><title>The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage</title><source>Springer Nature</source><creator>JIN, Y ; FULLER, L ; CARRENO, M ; ZUCKER, K ; ROTH, D ; ESQUENAZI, V ; KARATZAS, T ; SWANSON, S. J ; TZAKIS, A. G ; MILLER, J</creator><creatorcontrib>JIN, Y ; FULLER, L ; CARRENO, M ; ZUCKER, K ; ROTH, D ; ESQUENAZI, V ; KARATZAS, T ; SWANSON, S. J ; TZAKIS, A. G ; MILLER, J</creatorcontrib><description>Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC anti-CD3 monoclonal antibodies (mAb). One was a bright fluorescence intensity population (as in PBL), and the other dim. We calculated the number of FITC-anti-CD3 mAbs bound per lymphocyte on PBL and LIL and found 80,040 +/- 4628 and 39,615 +/- 3932, respectively. Therefore, HCV+ and HCV- patient PBL contained approximately twice the number of CD3 molecules per cell than patient CD3+ LIL. LIL also contained approximately a threefold higher concentration of TCR alpha beta +, CD4-CD8-, and CD56,16 (NK) cells than the patient PBL. Thus, a major subset of LIL is phenotypically similar to mouse NK1.1+ "intermediate" T cells. LIL freshly isolated from HCV+ livers exhibited weak CTL activity against EBV- or Con A-transformed lymphoblast targets infected with vaccinia-HCV recombinant virus (rHCV) or primary hepatocyte cultured cells. However, after in vitro coculture of LIL with rHCV, these cells developed a strong cytotoxicity for the above targets. In contrast, LIL from HCV- livers were not cytotoxic against the same targets. Histochemical studies (in situ) demonstrated that these hepatocytes express CD95, and stains demonstrated apoptosis. The HCV+ hepatocytes also express class I MHC molecules and ICAM-1. The addition of mAb specific for these adhesion molecules inhibited CML activity. Short-term cultured hepatocytes (targets) from HCV+ and HCV- patients produced low levels of cytokines IL-1 beta, IL-2, IL-6, TNF alpha, and IFN-gamma but a high level of IL-8. It is speculated that LIL expressing reduced numbers of CD3 molecules may even function as immune regulators as proposed for intermediate T cells in mice.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1023/a:1027326415164</identifier><identifier>PMID: 9083890</identifier><identifier>CODEN: JCIMDO</identifier><language>eng</language><publisher>New York, NY: Kluwer/Plenum</publisher><subject>Antibodies, Monoclonal - immunology ; Apoptosis ; Apoptosis - immunology ; Biological and medical sciences ; CD3 antigen ; CD3 Complex - immunology ; CD4 antigen ; CD56 antigen ; CD8 antigen ; CD95 antigen ; Cytokines - metabolism ; Cytotoxicity ; fas Receptor - metabolism ; Hepacivirus - immunology ; Hepatitis C - immunology ; Hepatocytes ; HLA Antigens - metabolism ; Human viral diseases ; Humans ; IL-1β ; Immunity, Cellular ; Infectious diseases ; Intercellular adhesion molecule 1 ; Intercellular Adhesion Molecule-1 - metabolism ; Interleukin 2 ; Interleukin 6 ; Interleukin 8 ; Liver ; Liver - immunology ; Liver Failure - immunology ; Liver Failure - pathology ; Liver Failure - physiopathology ; Lymphocytes ; Lymphocytes T ; Major histocompatibility complex ; Medical sciences ; Monoclonal antibodies ; Phenotype ; Receptors, Antigen, T-Cell - metabolism ; T-Lymphocyte Subsets - immunology ; Tumor necrosis factor-α ; Viral diseases ; Viral hepatitis ; γ-Interferon</subject><ispartof>Journal of clinical immunology, 1997-03, Vol.17 (2), p.140-153</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright Springer Science &amp; Business Media Mar 1997</rights><rights>Plenum Publishing Corporation 1997.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-b569cf8d1683aaf355b2aeffbc7643b77fc615e19df91172de7d6d40547891933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2609882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9083890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JIN, Y</creatorcontrib><creatorcontrib>FULLER, L</creatorcontrib><creatorcontrib>CARRENO, M</creatorcontrib><creatorcontrib>ZUCKER, K</creatorcontrib><creatorcontrib>ROTH, D</creatorcontrib><creatorcontrib>ESQUENAZI, V</creatorcontrib><creatorcontrib>KARATZAS, T</creatorcontrib><creatorcontrib>SWANSON, S. J</creatorcontrib><creatorcontrib>TZAKIS, A. G</creatorcontrib><creatorcontrib>MILLER, J</creatorcontrib><title>The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><description>Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC anti-CD3 monoclonal antibodies (mAb). One was a bright fluorescence intensity population (as in PBL), and the other dim. We calculated the number of FITC-anti-CD3 mAbs bound per lymphocyte on PBL and LIL and found 80,040 +/- 4628 and 39,615 +/- 3932, respectively. Therefore, HCV+ and HCV- patient PBL contained approximately twice the number of CD3 molecules per cell than patient CD3+ LIL. LIL also contained approximately a threefold higher concentration of TCR alpha beta +, CD4-CD8-, and CD56,16 (NK) cells than the patient PBL. Thus, a major subset of LIL is phenotypically similar to mouse NK1.1+ "intermediate" T cells. LIL freshly isolated from HCV+ livers exhibited weak CTL activity against EBV- or Con A-transformed lymphoblast targets infected with vaccinia-HCV recombinant virus (rHCV) or primary hepatocyte cultured cells. However, after in vitro coculture of LIL with rHCV, these cells developed a strong cytotoxicity for the above targets. In contrast, LIL from HCV- livers were not cytotoxic against the same targets. Histochemical studies (in situ) demonstrated that these hepatocytes express CD95, and stains demonstrated apoptosis. The HCV+ hepatocytes also express class I MHC molecules and ICAM-1. The addition of mAb specific for these adhesion molecules inhibited CML activity. Short-term cultured hepatocytes (targets) from HCV+ and HCV- patients produced low levels of cytokines IL-1 beta, IL-2, IL-6, TNF alpha, and IFN-gamma but a high level of IL-8. It is speculated that LIL expressing reduced numbers of CD3 molecules may even function as immune regulators as proposed for intermediate T cells in mice.</description><subject>Antibodies, Monoclonal - immunology</subject><subject>Apoptosis</subject><subject>Apoptosis - immunology</subject><subject>Biological and medical sciences</subject><subject>CD3 antigen</subject><subject>CD3 Complex - immunology</subject><subject>CD4 antigen</subject><subject>CD56 antigen</subject><subject>CD8 antigen</subject><subject>CD95 antigen</subject><subject>Cytokines - metabolism</subject><subject>Cytotoxicity</subject><subject>fas Receptor - metabolism</subject><subject>Hepacivirus - immunology</subject><subject>Hepatitis C - immunology</subject><subject>Hepatocytes</subject><subject>HLA Antigens - metabolism</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>IL-1β</subject><subject>Immunity, Cellular</subject><subject>Infectious diseases</subject><subject>Intercellular adhesion molecule 1</subject><subject>Intercellular Adhesion Molecule-1 - metabolism</subject><subject>Interleukin 2</subject><subject>Interleukin 6</subject><subject>Interleukin 8</subject><subject>Liver</subject><subject>Liver - immunology</subject><subject>Liver Failure - immunology</subject><subject>Liver Failure - pathology</subject><subject>Liver Failure - physiopathology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Major histocompatibility complex</subject><subject>Medical sciences</subject><subject>Monoclonal antibodies</subject><subject>Phenotype</subject><subject>Receptors, Antigen, T-Cell - metabolism</subject><subject>T-Lymphocyte Subsets - immunology</subject><subject>Tumor necrosis factor-α</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>γ-Interferon</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp1kM9rFTEUhYMo7bN13VUhqLgbmx-TZOJOHmqFgpvqdriT3PSlZGZek5nC---N-uii4Oosvo_DuZeQC84-cibkFXyqYaTQLVdcty_IhisjG6GseEk2FfHG8lacktel3DPGpBbqhJxY1snOsg2B2x3SOI7rhDQjuCU-xuVA85yQzoFeb381cfKrQ09TfMRM4xRiWjIscbqj6TDud7M7LFgqoDvcwzI7TGlNkKmHEe7wnLwKkAq-OeYZ-fn1y-32urn58e379vNN41rJl2ZQ2rrQea47CRCkUoMADGFwRrdyMCY4zRVy64Pl3AiPxmvfMtWaznIr5Rn58K93n-eHFcvSj7H82QITzmvpTVcPVsZW8d0z8X5e81S39UJbxWu9VdV6-1-rbrRS_626PErrMKLv9zmOkA_98b2Vvz9yKA5SyDC5WJ40oZntOiF_A0Z-iIU</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>JIN, Y</creator><creator>FULLER, L</creator><creator>CARRENO, M</creator><creator>ZUCKER, K</creator><creator>ROTH, D</creator><creator>ESQUENAZI, V</creator><creator>KARATZAS, T</creator><creator>SWANSON, S. J</creator><creator>TZAKIS, A. G</creator><creator>MILLER, J</creator><general>Kluwer/Plenum</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19970301</creationdate><title>The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage</title><author>JIN, Y ; FULLER, L ; CARRENO, M ; ZUCKER, K ; ROTH, D ; ESQUENAZI, V ; KARATZAS, T ; SWANSON, S. J ; TZAKIS, A. G ; MILLER, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-b569cf8d1683aaf355b2aeffbc7643b77fc615e19df91172de7d6d40547891933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibodies, Monoclonal - immunology</topic><topic>Apoptosis</topic><topic>Apoptosis - immunology</topic><topic>Biological and medical sciences</topic><topic>CD3 antigen</topic><topic>CD3 Complex - immunology</topic><topic>CD4 antigen</topic><topic>CD56 antigen</topic><topic>CD8 antigen</topic><topic>CD95 antigen</topic><topic>Cytokines - metabolism</topic><topic>Cytotoxicity</topic><topic>fas Receptor - metabolism</topic><topic>Hepacivirus - immunology</topic><topic>Hepatitis C - immunology</topic><topic>Hepatocytes</topic><topic>HLA Antigens - metabolism</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>IL-1β</topic><topic>Immunity, Cellular</topic><topic>Infectious diseases</topic><topic>Intercellular adhesion molecule 1</topic><topic>Intercellular Adhesion Molecule-1 - metabolism</topic><topic>Interleukin 2</topic><topic>Interleukin 6</topic><topic>Interleukin 8</topic><topic>Liver</topic><topic>Liver - immunology</topic><topic>Liver Failure - immunology</topic><topic>Liver Failure - pathology</topic><topic>Liver Failure - physiopathology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Major histocompatibility complex</topic><topic>Medical sciences</topic><topic>Monoclonal antibodies</topic><topic>Phenotype</topic><topic>Receptors, Antigen, T-Cell - metabolism</topic><topic>T-Lymphocyte Subsets - immunology</topic><topic>Tumor necrosis factor-α</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JIN, Y</creatorcontrib><creatorcontrib>FULLER, L</creatorcontrib><creatorcontrib>CARRENO, M</creatorcontrib><creatorcontrib>ZUCKER, K</creatorcontrib><creatorcontrib>ROTH, D</creatorcontrib><creatorcontrib>ESQUENAZI, V</creatorcontrib><creatorcontrib>KARATZAS, T</creatorcontrib><creatorcontrib>SWANSON, S. J</creatorcontrib><creatorcontrib>TZAKIS, A. G</creatorcontrib><creatorcontrib>MILLER, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JIN, Y</au><au>FULLER, L</au><au>CARRENO, M</au><au>ZUCKER, K</au><au>ROTH, D</au><au>ESQUENAZI, V</au><au>KARATZAS, T</au><au>SWANSON, S. J</au><au>TZAKIS, A. G</au><au>MILLER, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage</atitle><jtitle>Journal of clinical immunology</jtitle><addtitle>J Clin Immunol</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>17</volume><issue>2</issue><spage>140</spage><epage>153</epage><pages>140-153</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><coden>JCIMDO</coden><abstract>Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC anti-CD3 monoclonal antibodies (mAb). One was a bright fluorescence intensity population (as in PBL), and the other dim. We calculated the number of FITC-anti-CD3 mAbs bound per lymphocyte on PBL and LIL and found 80,040 +/- 4628 and 39,615 +/- 3932, respectively. Therefore, HCV+ and HCV- patient PBL contained approximately twice the number of CD3 molecules per cell than patient CD3+ LIL. LIL also contained approximately a threefold higher concentration of TCR alpha beta +, CD4-CD8-, and CD56,16 (NK) cells than the patient PBL. Thus, a major subset of LIL is phenotypically similar to mouse NK1.1+ "intermediate" T cells. LIL freshly isolated from HCV+ livers exhibited weak CTL activity against EBV- or Con A-transformed lymphoblast targets infected with vaccinia-HCV recombinant virus (rHCV) or primary hepatocyte cultured cells. However, after in vitro coculture of LIL with rHCV, these cells developed a strong cytotoxicity for the above targets. In contrast, LIL from HCV- livers were not cytotoxic against the same targets. Histochemical studies (in situ) demonstrated that these hepatocytes express CD95, and stains demonstrated apoptosis. The HCV+ hepatocytes also express class I MHC molecules and ICAM-1. The addition of mAb specific for these adhesion molecules inhibited CML activity. Short-term cultured hepatocytes (targets) from HCV+ and HCV- patients produced low levels of cytokines IL-1 beta, IL-2, IL-6, TNF alpha, and IFN-gamma but a high level of IL-8. It is speculated that LIL expressing reduced numbers of CD3 molecules may even function as immune regulators as proposed for intermediate T cells in mice.</abstract><cop>New York, NY</cop><pub>Kluwer/Plenum</pub><pmid>9083890</pmid><doi>10.1023/a:1027326415164</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0271-9142
ispartof Journal of clinical immunology, 1997-03, Vol.17 (2), p.140-153
issn 0271-9142
1573-2592
language eng
recordid cdi_proquest_miscellaneous_78890579
source Springer Nature
subjects Antibodies, Monoclonal - immunology
Apoptosis
Apoptosis - immunology
Biological and medical sciences
CD3 antigen
CD3 Complex - immunology
CD4 antigen
CD56 antigen
CD8 antigen
CD95 antigen
Cytokines - metabolism
Cytotoxicity
fas Receptor - metabolism
Hepacivirus - immunology
Hepatitis C - immunology
Hepatocytes
HLA Antigens - metabolism
Human viral diseases
Humans
IL-1β
Immunity, Cellular
Infectious diseases
Intercellular adhesion molecule 1
Intercellular Adhesion Molecule-1 - metabolism
Interleukin 2
Interleukin 6
Interleukin 8
Liver
Liver - immunology
Liver Failure - immunology
Liver Failure - pathology
Liver Failure - physiopathology
Lymphocytes
Lymphocytes T
Major histocompatibility complex
Medical sciences
Monoclonal antibodies
Phenotype
Receptors, Antigen, T-Cell - metabolism
T-Lymphocyte Subsets - immunology
Tumor necrosis factor-α
Viral diseases
Viral hepatitis
γ-Interferon
title The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-04T23%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immune%20reactivity%20role%20of%20HCV-induced%20liver%20infiltrating%20lymphocytes%20in%20hepatocellular%20damage&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=JIN,%20Y&rft.date=1997-03-01&rft.volume=17&rft.issue=2&rft.spage=140&rft.epage=153&rft.pages=140-153&rft.issn=0271-9142&rft.eissn=1573-2592&rft.coden=JCIMDO&rft_id=info:doi/10.1023/a:1027326415164&rft_dat=%3Cproquest_pubme%3E2695191195%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c431t-b569cf8d1683aaf355b2aeffbc7643b77fc615e19df91172de7d6d40547891933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216893679&rft_id=info:pmid/9083890&rfr_iscdi=true